Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7MW3711 versus docetaxel in previously treated advanced squamous non-small-cell lung cancer
ChiCTR2600132911Phase 3Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of 7MW3711 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Overall survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
7MW3711
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600132911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132911.